Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

27.43 +0.28 (+1.01%)
Streaming Delayed Price Updated: 11:37 AM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 173,931
Open 27.23
Bid (Size) 27.40 (100)
Ask (Size) 27.45 (100)
Prev. Close 27.15
Today's Range 26.52 - 27.59
52wk Range 13.36 - 30.09
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its... 
Via MarketMinute
News headline image
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that... 
Via MarketMinute
Topics Intellectual Property

Performance

YTD
+5.8%
+5.8%
1 Month
+10.4%
+10.4%
3 Month
+3.7%
+3.7%
6 Month
+10.5%
+10.5%
1 Year
+69.8%
+69.8%

More News

Read More
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
Via The Motley Fool
Immunovant Inc (NASDAQ:IMVT) Reports Q3 FY2026 Results, Beats EPS Estimates and Provides Key Clinical Updates ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Via Finterra
Topics Economy
News headline image
Air Taxi Stock Archer Aviation Draws $22.5 Million Institutional Buy. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish ↗
Via The Motley Fool
News headline image
Insights into Immunovant's Upcoming Earnings ↗
Via Benzinga
News headline image
Truth Social Stock Down 50% as One Investor Sells Off Nearly 800,000 Shares ↗
Via The Motley Fool
Topics Government
News headline image
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Immunovant (IMVT) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
Via Finterra
Topics ETFs Economy Initial Public Offering
News headline image
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunovant Inc (NASDAQ:IMVT) Stock Falls 10% on Q2 FY2026 Earnings and Corporate Updates ↗
Via Chartmill
News headline image
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗
Via Benzinga
News headline image
IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Immunovant Stock Blasted Higher Today ↗
Via The Motley Fool
News headline image
IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Immunovant Posts 34% R&D Jump in Q1 ↗
Via The Motley Fool
News headline image
IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
Via ACCESS Newswire
News headline image
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence ↗
Via Stocktwits

Frequently Asked Questions

Is Immunovant, Inc. - Common Stock publicly traded?
Yes, Immunovant, Inc. - Common Stock is publicly traded.
What exchange does Immunovant, Inc. - Common Stock trade on?
Immunovant, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immunovant, Inc. - Common Stock?
The ticker symbol for Immunovant, Inc. - Common Stock is IMVT on the Nasdaq Stock Market
What is the current price of Immunovant, Inc. - Common Stock?
The current price of Immunovant, Inc. - Common Stock is 27.43
When was Immunovant, Inc. - Common Stock last traded?
The last trade of Immunovant, Inc. - Common Stock was at 05/01/26 11:37 AM ET
What is the market capitalization of Immunovant, Inc. - Common Stock?
The market capitalization of Immunovant, Inc. - Common Stock is 3.15B
How many shares of Immunovant, Inc. - Common Stock are outstanding?
Immunovant, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.